NeuroMetrix (NASDAQ:NURO) Issues Quarterly Earnings Results

NeuroMetrix (NASDAQ:NURO) announced its earnings results on Tuesday. The medical device company reported ($0.75) earnings per share for the quarter, RTT News reports. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The business had revenue of $0.59 million for the quarter. During the same quarter in the prior year, the firm posted ($1.66) earnings per share.

NeuroMetrix Trading Up 6.4 %

Shares of NeuroMetrix stock opened at $3.84 on Friday. The company has a fifty day simple moving average of $4.03 and a 200-day simple moving average of $3.88. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The stock has a market cap of $7.78 million, a price-to-earnings ratio of -0.84 and a beta of 2.29.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of NeuroMetrix in a research note on Monday. They set a “sell” rating on the stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.